Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.

Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access

Glenview Capital Management, the firm founded by Larry Robbins (Trades, Portfolio), disclosed in regulatory filings that it boosted during February its holdings in Myriad Genetics Inc. ( MYGN , Financial) and Butterfly Network Inc. ( BFLY , Financial) according to GuruFocus Real-Time Picks, a Premium feature.

Larry Robbins' Firm Boosts 2 Health Care Stocks

Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.

Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Mark Verratti - Chief Commercial Officer. Conference Call Participants Tom Stevens - Cowen and Company Jack Meehan - Nephron Research Operator Greetings, and welcome to the Myriad Genetics Fourth Quarter 2022 Financial Earnings Conference Call.

Myriad Genetics, Inc. (MYGN) Q4 2022 Earnings Call Transcript

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates

SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on Tuesday, Feb. 28, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes.

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.